The MEK-ERK-Egr-1 axis and its regulation in cardiovascular disease

Area of Science:

• Molecular Biology
• Cardiovascular Research
• Biochemistry

Background:

• Cardiovascular disease (CVD) is a major global health concern, causing significant morbidity and mortality.
• Early growth response-1 (Egr-1), a zinc finger transcription factor, plays a critical role in CVD pathogenesis by regulating pro-inflammatory processes.
• Egr-1 activity is modulated by post-translational modifications and phosphorylation, notably through the MEK-ERK pathway.

Purpose of the Study:

• To review recent advancements in understanding the MEK-ERK-Egr-1 signaling cascade.
• To explore the regulatory factors and agents influencing Egr-1 activity in the context of CVD.
• To identify potential therapeutic targets within this pathway for CVD intervention.

Main Methods:

• Literature review of recent scientific progress on the MEK-ERK-Egr-1 cascade.
• Analysis of regulatory mechanisms involving various factors and agents impacting Egr-1.
• Synthesis of information on post-translational modifications and kinase activity affecting Egr-1.

Main Results:

• The MEK-ERK-Egr-1 cascade is a key regulator of inflammatory processes in CVD.
• Egr-1 activity is influenced by diverse factors including TET2, TRIB2, MIAT, SphK1, cAMP, teneligliptin, cholinergic drugs, red wine, flavonoids, wogonin, febuxostat, docosahexaenoic acid, and AT1R blockade.
• Post-translational modifications like sumoylation, ubiquitination, and acetylation further modulate Egr-1 function.

Conclusions:

• The MEK-ERK-Egr-1 pathway presents a promising target for novel therapeutic strategies against CVD.
• Understanding the intricate regulation of Egr-1 by various factors opens avenues for drug development.
• Targeting this cascade could lead to effective interventions for reducing CVD morbidity and mortality.